Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Zileuton™ loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells

  • Gener, P.
  • Montero, S.
  • Xandri-Monje, H.
  • Díaz-Riascos, Z.V.
  • Rafael, D.
  • Andrade, F.
  • Martínez-Trucharte, F.
  • González, P.
  • Seras-Franzoso, J.
  • Manzano, A.
  • Arango, D.
  • Sayós, J.
  • Abasolo, I.
  • Schwartz, S.Jr
Tumor recurrence, metastatic spread and progressive gain of chemo-resistance of advanced cancers are sustained by the presence of cancer stem cells (CSCs) within the tumor. Targeted therapies with the aim to eradicate these cells are thus highly regarded. However, often the use of new anti-cancer therapies is hampered by pharmacokinetic demands. Drug delivery through nanoparticles has great potential to increase efficacy and reduce toxicity and adverse effects. However, its production has to be based on intelligent design. Likewise, we developed polymeric nanoparticles loaded with Zileuton™, a potent inhibitor of cancer stem cells (CSCs), which was chosen based on high throughput screening. Its great potential for CSCs treatment was subsequently demonstrated in in vitro and in in vivo CSC fluorescent models. Encapsulated Zileuton™ reduces amount of CSCs within the tumor and effectively blocks the circulating tumor cells (CTCs) in the blood stream and metastatic spread.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies

  • Pesarrodona, Mireia
  • Jauset González, Antoni
  • Sánchez-Chardi, Alejandro
  • Seras Franzoso, Joaquin
  • Baltà Foix, Ricardo
  • Mancilla Zamora, Sandra
  • Fernández Amurgo, Yolanda
  • Schwartz Navarro, Simon
  • Abasolo Olaortua, Ibane
  • Diaz Riascos, Zamira Vanessa
  • Beaulieu, Marie-Eve
  • Soucek, Laura
Biofabrication; Cancer therapy; Functional amyloids, Biofabricación; Terapia contra el cáncer; Amiloides funcionales, Biofabricació; Teràpia contra el càncer; Amiloides funcionals, Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins., This study has been supported by La Fundacio Marato TV3 and NanoCanTri (CIBER-BBN) to E.V. and I.A., and partially by ISCIII (PI15/00272 and PI1702242 co-founded by Fondo Europeo de Desarrollo Regional (FEDER), to E.V. and S.S., respectively), and Agencia Estatal de Investigacion (AEI) and FEDER (BIO2016-76063-R, AEI/FEDER, UE), AGAUR (2017SGR-229) and CIBER-BBN (VENOM4CANCER) granted to A.V. Protein production and DLS have been partially performed by the ICTS "NANBIOSIS," more specifically by the Protein Production Platform of CIBER-BBN/IBB () and the Biomaterial Processing and Nanostructuring Unit (), respectively. Biodistribution and immunohistochemistry assays were performed at the ICTS "NANBIOSIS," specifically by U20/FVPR (). L.S.-G. was supported by predoctoral fellowship from AGAUR (2018FI_B2_00051). L.S. was supported by the European Research Council (CoG #617473) and the Instituto de Salud Carlos III (FIS #PI16/01224). J.S.-F. was supported by an AECC post-doctoral fellowship. A.V. received an ICREA ACADEMIA award
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pivotal role of AKT2 during dynamic phenotypic change of breast cancer stem cells

  • Gener, Petra|||0000-0002-2250-570X
  • Rafael, Diana|||0000-0003-3180-3028
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Pérez Martín, Anna
  • Alamo Pindado, Luis
  • Casas, Glòria
  • Arango, Diego|||0000-0003-2953-3284
  • Fernández Caparrós, Yolanda
  • Díaz Riascos, Zamira Vanessa|||0000-0003-1595-618X
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Schwartz, Simon|||0000-0001-8297-7971
Therapeutic resistance seen in aggressive forms of breast cancer remains challenging for current treatments. More than half of the patients suffer from a disease relapse, most of them with distant metastases. Cancer maintenance, resistance to therapy, and metastatic disease seem to be sustained by the presence of cancer stem cells (CSC) within a tumor. The difficulty in targeting this subpopulation derives from their dynamic interconversion process, where CSC can differentiate to non-CSC, which in turn de-differentiate into cells with CSC properties. Using fluorescent CSC models driven by the expression of ALDH1A 1(aldehyde dehydrogenase 1A1), we confirmed this dynamic phenotypic change in MDA-MB-231 breast cancer cells and to identify Serine/Threonine Kinase 2 (AKT2) as an important player in the process. To confirm the central role of AKT2, we silenced AKT2 expression via small interfering RNA and using a chemical inhibitor (CCT128930), in both CSC and non-CSC from different cancer cell lines. Our results revealed that AKT2 inhibition effectively prevents non-CSC reversion through mesenchymal to epithelial transition, reducing invasion and colony formation ability of both, non-CSC and CSC. Further, AKT2 inhibition reduced CSC survival in low attachment conditions. Interestingly, in orthotopic tumor mouse models, high expression levels of AKT2 were detected in circulating tumor cells (CTC). These findings suggest AKT2 as a promising target for future anti-cancer therapies at three important levels: (i) Epithelial-to-mesenchymal transition (EMT) reversion and maintenance of CSC subpopulation in primary tumors, (ii) reduction of CTC and the likelihood of metastatic spread, and (iii) prevention of tumor recurrence through inhibition of CSC tumorigenic and metastatic potential.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Engineering a nanostructured nucleolin-binding peptide for intracellular drug delivery in triple-negative breast cancer stem cells

  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Baltà Foix, Ricardo
  • Cámara-Sánchez, Patricia|||0000-0003-1958-9735
  • Gener, Petra|||0000-0002-2250-570X
  • Jara, José Juan
  • Pulido, Daniel|||0000-0002-2841-194X
  • Serna, Naroa|||0000-0001-5682-8198
  • Schwartz, Simon|||0000-0001-8297-7971
  • Royo, Miriam|||0000-0001-5292-0819
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Vázquez, Esther|||0000-0003-1052-0424
Five peptide ligands of four different cell surface receptors (nucleolin, CXCR1, CMKLR1, and CD44v6) have been evaluated as targeting moieties for triple-negative human breast cancers. Among them, the peptide F3, derived from phage display, promotes the fast and efficient internalization of a genetically fused green fluorescent protein (GFP) inside MDA-MB-231 cancer stem cells in a specific receptor-dependent fashion. The further engineering of this protein into the modular construct F3-RK-GFP-H6 and the subsequent construct F3-RK-PE24-H6 resulted in self-assembling polypeptides that organize as discrete and regular nanoparticles. These materials, 15-20 nm in size, show enhanced nucleolin-dependent cell penetrability. We show that the F3-RK-PE24-H6, based on the Pseudomonas aeruginosa exotoxin A (PE24) as a core functional domain, is highly cytotoxic over target cells. The combination of F3, the cationic peptide (RK), and the toxin domain PE24 in such unusual presentation appears as a promising approach to cell-targeted drug carriers in breast cancers and addresses selective drug delivery in otherwise difficult-to-treat triple-negative breast cancers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Extracellular Vesicles as Drug Delivery Systems in Cancer

  • Hernández Oller, Laia|||0000-0003-4116-6595
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Andrade, Fernanda|||0000-0002-4947-2346
  • Rafael, Diana|||0000-0003-3180-3028
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Gener, Petra|||0000-0002-2250-570X
  • Schwartz, Simon|||0000-0001-8297-7971
Within tumors, Cancer Stem Cell (CSC) subpopulation has an important role in maintaining growth and dissemination while preserving high resistance against current treatments. It has been shown that, when CSCs are eliminated, the surrounding Differentiated Cancer Cells (DCCs) may reverse their phenotype and gain CSC-like features to preserve tumor progression and ensure tumor survival. This strongly suggests the existence of paracrine communication within tumor cells. It is evidenced that the molecular crosstalk is at least partly mediated by Extracellular Vesicles (EVs), which are cell-derived membranous nanoparticles that contain and transport complex molecules that can affect and modify the biological behavior of distal cells and their molecular background. This ability of directional transport of small molecules prospects EVs as natural Drug Delivery Systems (DDS). EVs present inherent homing abilities and are less immunogenic than synthetic nanoparticles, in general. Currently, strong efforts are focused into the development and improvement of EV-based DDS. Even though EV-DDS have already reached early phases in clinical trials, their clinical application is still far from commercialization since protocols for EVs loading, modification and isolation need to be standardized for large-scale production. Here, we summarized recent knowledge regarding the use of EVs as natural DDS against CSCs and cancer resistance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dynamism, Sensitivity, and Consequences of Mesenchymal and Stem-Like Phenotype of Cancer Cells

  • Gener, Petra|||0000-0002-2250-570X
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Callejo, Patricia González
  • Andrade, Fernanda|||0000-0002-4947-2346
  • Rafael, Diana|||0000-0003-3180-3028
  • Martínez, Francesc
  • Montero, Sara
  • Arango, Diego|||0000-0003-2953-3284
  • Sayós, Joan|||0000-0002-4664-3461
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Schwartz, Simon|||0000-0001-8297-7971
There are remarkable similarities in the description of cancer stem cells (CSCs) and cancer cells with mesenchymal phenotype. Both cell types are highly tumorigenic, resistant against common anticancer treatment, and thought to cause metastatic growth. Moreover, cancer cells are able to switch between CSC and non-CSC phenotypes and vice versa, to ensure the necessary balance within the tumor. Likewise, cancer cells can switch between epithelial and mesenchymal phenotypes via well-described transition (EMT/MET) that is thought to be crucial for tumor propagation. In this review, we discuss whether, and to which extend, the CSCs and mesenchymal cancer cells are overlapping phenomena in terms of mechanisms, origin, and implication for cancer treatment. As well, we describe the dynamism of both phenotypes and involvement of the tumor microenvironment in CSC reversion and in EMT.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics

  • Ulldemolins, Anna|||0000-0001-8825-9436
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Andrade, Fernanda|||0000-0002-4947-2346
  • Rafael, Diana|||0000-0003-3180-3028
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Gener, Petra|||0000-0002-2250-570X
  • Schwartz, Simon|||0000-0001-8297-7971
Advanced cancer is still considered an incurable disease because of its metastatic spread to distal organs and progressive gain of chemoresistance. Even though considerable treatment progress and more effective therapies have been achieved over the past years, recurrence in the long-term and undesired side effects are still the main drawbacks of current clinical protocols. Moreover, a majority of chemotherapeutic drugs are highly hydrophobic and need to be diluted in organic solvents, which cause high toxicity, in order to reach effective therapeutic dose. These limitations of conventional cancer therapies prompted the use of nanomedicine, the medical application of nanotechnology, to provide more effective and safer cancer treatment. Potential of nanomedicines to overcome resistance, ameliorate solubility, improve pharmacological profile, and reduce adverse effects of chemotherapeutical drugs is thus highly regarded. Their use in the clinical setting has increased over the last decade. Among the various existing nanosystems, nanoparticles have the ability to transform conventional medicine by reducing the adverse effects and providing a controlled release of therapeutic agents. Also, their small size facilitates the intracellular uptake. Here, we provide a closer review of clinical prospects and mechanisms of action of nanomedicines to overcome drug resistance. The significance of specific targeting towards cancer cells is debated as well.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies

  • Pesarrodona, Mireia
  • Jauset González, Antoni
  • Sánchez-Chardi, Alejandro
  • Seras Franzoso, Joaquin
  • Baltà Foix, Ricardo
  • Mancilla Zamora, Sandra
  • Fernández Amurgo, Yolanda
  • Schwartz Navarro, Simon
  • Abasolo Olaortua, Ibane
  • Diaz Riascos, Zamira Vanessa
  • Beaulieu, Marie-Eve
  • Soucek, Laura
Biofabrication; Cancer therapy; Functional amyloids, Biofabricación; Terapia contra el cáncer; Amiloides funcionales, Biofabricació; Teràpia contra el càncer; Amiloides funcionals, Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins., This study has been supported by La Fundacio Marato TV3 and NanoCanTri (CIBER-BBN) to E.V. and I.A., and partially by ISCIII (PI15/00272 and PI1702242 co-founded by Fondo Europeo de Desarrollo Regional (FEDER), to E.V. and S.S., respectively), and Agencia Estatal de Investigacion (AEI) and FEDER (BIO2016-76063-R, AEI/FEDER, UE), AGAUR (2017SGR-229) and CIBER-BBN (VENOM4CANCER) granted to A.V. Protein production and DLS have been partially performed by the ICTS "NANBIOSIS," more specifically by the Protein Production Platform of CIBER-BBN/IBB () and the Biomaterial Processing and Nanostructuring Unit (), respectively. Biodistribution and immunohistochemistry assays were performed at the ICTS "NANBIOSIS," specifically by U20/FVPR (). L.S.-G. was supported by predoctoral fellowship from AGAUR (2018FI_B2_00051). L.S. was supported by the European Research Council (CoG #617473) and the Instituto de Salud Carlos III (FIS #PI16/01224). J.S.-F. was supported by an AECC post-doctoral fellowship. A.V. received an ICREA ACADEMIA award